Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 4/20 | 0.37 |
| ▸ | CASP3 | P42574 | 5/20 | 0.34 |
| ▸ | CASP7 | P55210 | 2/20 | 0.34 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | FER | P16591 | 1/20 | 0.33 |
| ▸ | LTK | P29376 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9152783 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL4206081 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL4909203 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL4026807 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL8938070 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL31036258 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL9151570 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL1234203 | 0.98 | GSK3B (0.39) | GSK3BKDM4EALDH1A1GAAHPGD | |
| Phthalimide SCHEMBL8559536 | 0.97 | GSK3B (0.44) | GSK3BKDM4EALDH1A1GAAHPGD | |
| Phthalimide SCHEMBL8558696 | 0.96 | GSK3B (0.43) | GSK3BKDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114773222-A | Synthetic method of azo micromolecules for zinc oxide nanoparticle stable ligand | 宁波大学 | 2022-07-22 | — | — | CN | claimed |
| EP-4700124-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250075208-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2025-03-06 | — | — | US | disclosed |
| EP-4496590-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) MOLECULE FOR DEGRADATION OF ENL AND CANCER THERAPY | Baylor College of Medicine (US) | 2025-01-29 | — | — | EP | disclosed |
| US-12173288-B2 | Oligonucleotide-ligand conjugates and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| CN-114773222-B | Synthesis method of azo micromolecules for zinc oxide nanoparticle stable ligand | 宁波大学 | 2024-04-09 | — | — | CN | disclosed |
| WO-2023183412-A1 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) MOLECULE FOR DEGRADATION OF ENL AND CANCER THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20220348914-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2022-11-03 | — | — | US | disclosed |
| EP-4039278-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| CN-114773222-A | Synthetic method of azo micromolecules for zinc oxide nanoparticle stable ligand | 宁波大学 | 2022-07-22 | — | — | CN | disclosed |
| EP-0728139-A1 | AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-28 | — | — | EP | disclosed |
| US-5543507-A | BONDING STRANDS OR ONE STRAND AT DIFFERENT SITES; RNA MIMICS FIXED IN SPATIAL CONFORMATION; NUCLEASE RESISTANT MIMICS OF BINDING RECEPTORS FOR NUCLEIC ACID-BINDING PROTEINS; 5-LIPOXYGENASE INHIBITORS; DIAGNOSIS; ANALYZING | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-06 | — | — | US | disclosed |
| EP-0635023-A4 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES. | ISIS PHARMACEUTICALS INC (US) | 1996-03-20 | — | — | EP | disclosed |
| US-5424451-A | Used as cholinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1995-06-13 | — | — | US | disclosed |
| WO-1995006659-A1 | AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-03-09 | — | — | WO | disclosed |
| EP-0635023-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5302593-A | Aminoalkylcarbamic esters of eseroline suitable for use as chlorinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1994-04-12 | — | — | US | disclosed |
| EP-0575954-A1 | Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1993-12-29 | — | — | EP | disclosed |
| WO-1993018052-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
| US-4705892-A | Process for preparing alpha,omega-diamino acids | MERCK & CO., INC. (US) | 1987-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348914-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | GSK3B 4633/4885KDM4E 4685/4885ALDH1A1 1084/4885 |
| US-12173288-B2 | Oligonucleotide-ligand conjugates and process for their preparation | IGF2R, IRS1, INSR | GSK3B 4633/4885KDM4E 4685/4885ALDH1A1 1084/4885 |
| US-20250075208-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | GSK3B 4633/4885KDM4E 4685/4885ALDH1A1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.